Logo for Sana Biotechnology Inc

Sana Biotechnology Investor Relations Material

Latest events

Logo for Sana Biotechnology Inc

R&D Day 2023

Sana Biotechnology
Logo for Sana Biotechnology

Q4 2023

29 Feb, 2024
Logo for Sana Biotechnology

Corporate Presentation

15 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Sana Biotechnology Inc

Access all reports
Sana Biotechnology Inc. is a biotechnology company focusing on the development of engineered cells as medicines. The company focuses on both ex vivo and in vivo cell engineering platforms to address a variety of therapeutic areas with significant unmet needs, including oncology, diabetes, central nervous system disorders, and autoimmune diseases among others. Sana Biotechnology's approach involves the use of cutting-edge technologies such as CRISPR for gene editing and their proprietary platforms, Fusogen for in vivo cell engineering, and a hyperimmune platform for ex vivo cell engineering. They are actively investigating potential treatments for conditions such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and diabetes, to name a few. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.